Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial

Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial

Hereditary hemorrhagic telangiectasia is a rare but ubiquitous genetic disease. Epistaxis is the most frequent and life-threatening manifestation and tacrolimus, an immunosuppressive agent, appears to be an interesting new treatment option because of its anti-angiogenic properties. Our objective was...

Full description

Bibliographic Details
Main Authors: Sophie Dupuis-Girod, Anne-Emmanuelle Fargeton, Vincent Grobost, Sophie Rivière, Marjolaine Beaudoin, Evelyne Decullier, Lorraine Bernard, Valentine Bréant, Bettina Colombet, Pierre Philouze, Sabine Bailly, Frédéric Faure, Ruben Hermann
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Journal of Clinical Medicine
Subjects:
hereditary hemorrhagic telangiectasia
epistaxis
nosebleeds
tacrolimus
nasal ointment
genetic disease
Online Access:https://www.mdpi.com/2077-0383/9/5/1262

Internet

https://www.mdpi.com/2077-0383/9/5/1262

Similar Items